provider image
Welcome! You’re in GoodRx for healthcare professionals. Now, you’ll enjoy a streamlined experience created specifically for healthcare professionals.
Skip to main content
HomeHealthcare AccessResearch

GoodRx Research Data Description

Jeroen van Meijgaard, PhD
Published on April 24, 2020
This article is no longer being updated and some information may not be current. Visit the GoodRx Health homepage for our latest articles.

GoodRx aims to provide the highest level of quality research about drugs, their availability and their cost. To fulfill this aim, the company supplements the data generated internally with data from external sources. The GoodRx Research team leverages these sources to track drug utilization, drug pricing, and drug shortages, and inform patients that may be impacted. Some of these sources are in the public domain, provided by the government generally, while other data sources are licensed. This document describes the coverage of licensed data and potential use to describe drug trends and utilization patterns in the United States.

GoodRx Research logo: Yellow plus sign or cross icon with the wordmark below that reads "GoodRx Research."

GoodRx uses a representative sample of de-identified pharmacy claims across the United States, representing a wide range of channels and providers. Data includes the drug and quantity that was dispensed, the location and date of the transaction, and the usual and customary cost (U&C) of the product that was dispensed. The U&C cost is what would be paid by the patient in the absence of a contracted rate, or insurance price. 

These data do not include any personal identifiers, and do not include information on what was paid for the medication.

The GoodRx Research team combines these claims with information on drugs from the GoodRx proprietary drug database and data on pharmacies to analyze trends in utilization and variation across geographic locales for specific drugs, classes of drugs, and medical conditions for which different drugs are prescribed.

Read the full report here.

Co-contributors: Diane Li, Tori Marsh, MPH, and Amanda Nguyen, PhD

why trust our exports reliability shield

Why trust our experts?

Jeroen van Meijgaard, PhD
Dr. van Meijgaard is a health economist with over 20 years of experience in healthcare informatics and has a knack for distilling meaningful insights from data. With extensive expertise in population research and the social, economic, and environmental determinants of health, Dr. van Meijgaard has published in leading academic journals.
Tori Marsh, MPH
Edited by:
Tori Marsh, MPH
Tori Marsh is GoodRx’s resident expert on prescription drug pricing, prescribing trends, and drug savings. She oversees the GoodRx drug database, ensuring that all drug information is accurate and up to date.

Was this page helpful?

Subscribe and save.

Get prescription saving tips and more from GoodRx Health. Enter your email to sign up.

By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.

Related Articles